Press release - No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phas ...

With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a ...

Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock fell.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...